| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 54, Issue 4, 599-618, December 2002
Laboratory of Pediatrics and Neurology, University Medical Center,
Nijmegen, The Netherlands (A.d.B., L.A.J.K., H.J.B.) and Department of
Chronic Disease Epidemiology, National Institute of Public Health and
the Environment, The Netherlands (A.d.B., W.M.M.V., D.K.).
I. Introduction
II. History of Homocysteine As a Risk Factor for Vascular Diseases
III. Homocysteine Metabolism
IV. Determinants of Homocysteine Concentration in the General
Population
A. Age and Sex
B. Supplemental and Dietary B Vitamin Intake
C. Lifestyle factors
1. Coffee.
2. Smoking.
3. Alcohol.
4. Physical Activity.
D. Genetics
E. Biological Coronary Heart Disease Risk Factors
V. Drugs and Diseases As Determinants of Homocysteine
Concentrations
A. Drugs Influencing the Homocysteine Concentration
1. Hormones.
2. Antiepileptic Drugs.
3. Methotrexate.
4. Nitrous Oxide.
5. Other Drugs That Have an Effect on the Homocysteine
Concentration.
B. Diseases That Influence the Homocysteine Concentration
1. Kidney Dysfunction.
2. Proliferating Diseases.
3. Rheumatoid Arthritis.
4. Endocrine Disorders.
5. Intestinal Diseases.
VI. Homocysteine and the Risk of Coronary Heart Disease
A. Inborn Errors
B. Retrospective, Cross-Sectional, and Prospective Epidemiological
Studies
C. Homocysteine and Thrombosis
D. Methylenetetrahydrofolate Reductase 677C>T Genotype and
Coronary Heart Disease
E. Mechanism by Which Homocysteine Increases the Risk of Coronary
Heart Disease
1. In Vitro Studies.
2. Studies in Patients with Homocystinuria.
3. Studies on Homocysteine and Endothelial Function.
4. Studies on Homocysteine and Endothelium-Derived Nitric
Oxide.
F. Intervention Trials
G. Conclusion about the Relationship between Homocysteine and
Coronary Heart Disease
VII. Directions for Future Research
VIII. Implications for Prevention and Treatment
Acknowledgments
References
Cardiovascular diseases (CVD), especially coronary heart disease (CHD), are the most important causes of death in industrialized countries. Increased concentrations of total plasma homocysteine (tHcy) have been associated with an increased risk of CHD. Assuming that this relation is causal, a lower tHcy concentration will reduce the occurrence and recurrence of CHD. Therefore, it is important to know which factors determine the tHcy concentration. In the general population, the most important modifiable determinants of tHcy are folate intake and coffee consumption. Smoking and alcohol consumption are also associated with the tHcy concentration, but more research is necessary to elucidate whether these relations are not originating from residual confounding due to other lifestyle factors. The most important nonmodifiable determinant is the 677 C>T polymorphism in the gene that encodes methylenetetrahydrofolate reductase (MTHFR), a regulating enzyme in homocysteine metabolism. Especially subjects with the homozygous form of this polymorphism (i.e., 677TT genotype) and a low folate status have elevated tHcy concentrations. Specific clinical conditions like the use of antiepileptic drugs or methotrexate, renal failure, cancer, rheumatoid arthritis, and hypothyroidism may lead to elevated tHcy concentrations. The available epidemiological evidence indicates that an increased tHcy concentration is not an important risk factor for CHD in healthy subjects. However, prospective studies, which included subjects at high risk of CHD, and secondary prevention trials with intermediary endpoints consistently show that elevations in the tHcy concentration may be an important risk factor in these subjects for a (recurrent) CHD event. The induction of vascular endothelial dysfunction by homocysteine may underlie this increased risk. Ongoing intervention trials will indicate whether homocysteine-lowering through vitamin supplementation, prevents CHD in the treatment groups.
This article has been cited by other articles:
|
|
 |
|
  R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. I. Holm, S. Hustad, P. M. Ueland, S. E. Vollset, T. Grotmol, and J. Schneede Modulation of the Homocysteine-Betaine Relationship by Methylenetetrahydrofolate Reductase 677 C->T Genotypes and B-Vitamin Status in a Large-Scale Epidemiological Study J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1535 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. H. Meng, G. Yang, W. Yang, B. Jiang, L. Wu, and R. Wang Protective Effect of Hydrogen Sulfide on Balloon Injury-Induced Neointima Hyperplasia in Rat Carotid Arteries Am. J. Pathol., April 1, 2007; 170(4): 1406 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Fukada, M. Setoue, T. Morita, and K. Sugiyama Dietary Eritadenine Suppresses Guanidinoacetic Acid-Induced Hyperhomocysteinemia in Rats J. Nutr., November 1, 2006; 136(11): 2797 - 2802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Dinleyici, B. Kirel, O. Alatas, H. Muslumanoglu, Z. Kilic, and N. Dogruel Plasma Total Homocysteine Levels in Children with Type 1 Diabetes: Relationship with Vitamin Status, Methylene Tetrahydrofolate Reductase Genotype, Disease Parameters and Coronary Risk Factors J Trop Pediatr, August 1, 2006; 52(4): 260 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Patterson, P R Flatt, L Brennan, P Newsholme, and N H McClenaghan Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic {beta}-cell glucose metabolism and insulin secretion. J. Endocrinol., May 1, 2006; 189(2): 301 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cho, S. H Zeisel, P. Jacques, J. Selhub, L. Dougherty, G. A Colditz, and W. C Willett Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ulrich, K. Curtin, J. D. Potter, J. Bigler, B. Caan, and M. L. Slattery Polymorphisms in the Reduced Folate Carrier, Thymidylate Synthase, or Methionine Synthase and Risk of Colon Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2509 - 2516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Ebbesen and J. Ingerslev Folate Deficiency-Induced Hyperhomocysteinemia Attenuates, and Folic Acid Supplementation Restores, the Functional Activities of Rat Coagulation Factors XII, X, and II J. Nutr., August 1, 2005; 135(8): 1836 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. P. M. Eussen, L. C. P. G. M. de Groot, R. Clarke, J. Schneede, P. M. Ueland, W. H. L. Hoefnagels, and W. A. van Staveren Oral Cyanocobalamin Supplementation in Older People With Vitamin B12 Deficiency: A Dose-Finding Trial Arch Intern Med, May 23, 2005; 165(10): 1167 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Coppen and C. Bolander-Gouaille Treatment of depression: time to consider folic acid and vitamin B12 J Psychopharmacol, January 1, 2005; 19(1): 59 - 65. [Abstract] [PDF]
|
|
|
|
|
|
P. Happonen, S. Voutilainen, and J. T. Salonen Coffee Drinking Is Dose-Dependently Related to the Risk of Acute Coronary Events in Middle-Aged Men J. Nutr., September 1, 2004; 134(9): 2381 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Gao, O. I. Bermudez, and K. L. Tucker Plasma C-Reactive Protein and Homocysteine Concentrations Are Related to Frequent Fruit and Vegetable Intake in Hispanic and Non-Hispanic White Elders J. Nutr., April 1, 2004; 134(4): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Faraci and S. R. Lentz Hyperhomocysteinemia, Oxidative Stress, and Cerebral Vascular Dysfunction Stroke, February 1, 2004; 35(2): 345 - 347. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Davis, P. W. Stacpoole, J. Williamson, L. S. Kick, E. P. Quinlivan, B. S. Coats, B. Shane, L. B. Bailey, and J. F. Gregory III Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E272 - E279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kimura, K. Umegaki, M. Higuchi, P. Thomas, and M. Fenech Methylenetetrahydrofolate Reductase C677T Polymorphism, Folic Acid and Riboflavin Are Important Determinants of Genome Stability in Cultured Human Lymphocytes J. Nutr., January 1, 2004; 134(1): 48 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Bagi, C. Cseko, E. Toth, and A. Koller Oxidative stress-induced dysregulation of arteriolar wall shear stress and blood pressure in hyperhomocysteinemia is prevented by chronic vitamin C treatment Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2277 - H2283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Hackam and S. S. Anand Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence JAMA, August 20, 2003; 290(7): 932 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Holmquist, S. Larsson, A. Wolk, and U. de Faire Multivitamin Supplements Are Inversely Associated with Risk of Myocardial Infarction in Men and Women--Stockholm Heart Epidemiology Program (SHEEP) J. Nutr., August 1, 2003; 133(8): 2650 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kreisberg and A. Oberman Medical Management of Hyperlipidemia/Dyslipidemia J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2445 - 2461. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
